ストックスクリーナーアプリを入手
2.31
3.12%
0.07
プレマーケット:
2.32
0.010
+0.43%
Immunitybio Inc (IBRX) 最新ニュース
ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates - MSN
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID - BioSpace
ImmunityBio Settled With Investors Over FDA Rejection Drama— How to Claim Your Share - TradingView
Q2 2025 CRO Activity and Intel Report Featuring ICON, AstraZeneca, Akesobio, CSPPC Pharmaceutical, ImmunityBio, BoryungResearchAndMarkets.com - FinancialContent
ImmunityBio Launching New Phase 2 Trial of Anktiva to Treat Long COVID - MarketScreener
ImmunityBio launches phase 2 study of ANKTIVA for long COVID - Investing.com
ImmunityBio Inc. Stock Flags Risk Zone in Volatility IndexJuly 2025 EndofMonth & Entry Point Confirmation Signals - sundaytimes.kr
ImmunityBio Wins U.K. Approval - Los Angeles Business Journal
Fibonacci Retracement Aligns with Support in ImmunityBio Inc.July 2025 News Drivers & Fast Momentum Entry Tips - newsimpact.co.kr
Published on: 2025-08-17 09:14:13 - metal.it
Heatmap Data Shows High Activity in ImmunityBio Inc. Sector2025 Earnings Surprises & Fast Exit/Entry Strategy Plans - sundaytimes.kr
Is ImmunityBio Inc.’s growth already priced inMarket Performance Recap & AI Powered Market Trend Analysis - thegnnews.com
Is ImmunityBio Inc. a speculative investmentTrade Volume Report & Fast Gain Swing Alerts - sundaytimes.kr
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results - MSN
Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter - Oncodaily
ImmunityBio ($IBRX) Is Paying a $10.5M Settlement to Investors — Here’s How to Get Your Share - TradingView
Is ImmunityBio Inc. stock a value trap2025 Valuation Update & Expert Verified Stock Movement Alerts - thegnnews.com
ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates - ADVFN Brasil
RSI + MACD Show Convergence for ImmunityBio Inc.2025 Price Targets & Growth Focused Stock Pick Reports - sundaytimes.kr
ImmunityBio’s Anktiva Study: A Potential Breakthrough for Long COVID Treatment - TipRanks
ImmunityBio shares fall 1.95% intraday after Q2 net loss and revenue rise. - AInvest
Why ImmunityBio (IBRX) Is Up 18.5% After Early VA Uptake of ANKTIVA and Improving Financials - simplywall.st
ImmunityBio higher after early-stage trial results for cell therapy in lymphoma - MSN
ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy - BioSpace
ImmunityBio stock surges on promising trial results for lymphoma treatment, analysts forecast significant upside potential. - AInvest
ImmunityBio Shares Rise After 'Promising' Results From Lymphoma Treatment - MarketScreener
Hillenbrand, ImmunityBio, V2X - TradingView
ImmunityBio Surges 15% on Groundbreaking Cancer Trial Results: A New Era for NK Cell Therapy? - AInvest
ImmunityBio announces early findings from QUILT-106 trial - TipRanks
ImmunityBio’s Q2 Earnings Surge Due to ANKTIVA Success - StocksToTrade
Lumentum Holdings, ImmunityBio, V2X - TradingView
ImmunityBio Stock Surges on Robust Q2 Earnings Report - timothysykes.com
Immunitybio stock soars after promising cancer therapy trial results By Investing.com - Investing.com Canada
ImmunityBio's NK cell therapy shows promise in lymphoma trial. - AInvest
ImmunityBio up on trial data for cell therapy (IBRX:NASDAQ) - Seeking Alpha
ImmunityBio rises after early data for blood cancer cell therapy - TradingView
ImmunityBio’s Stock Surges on Promising Trial Results - TipRanks
CD19 CAR-NK therapy shows complete responses in late-stage lymphoma - Investing.com Canada
VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients - Vax-Before-Travel
ImmunityBio shares rise 1.21% premarket after ANKTIVA treatment approval for bladder cancer. - AInvest
ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients - MarketScreener
ImmunityBio’s Shareholder Settlement Gains Preliminary Approval - The Globe and Mail
ImmunityBio Shareholder Settlement Gains Preliminary Approval, Boosting Company's Future Prospects - AInvest
Investors Can Still File Late Claims in ImmunityBio Settlement — Here’s How to Get Your Share - TradingView
Why Investors Shouldn't Be Surprised By ImmunityBio, Inc.'s (NASDAQ:IBRX) P/S - 富途牛牛
Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
Q2 2025 Revenue Up 5% YoY to $1,241mln; Raises FY23 Guidance, Innovation Target. - AInvest
ImmunityBio Q2 Earnings Show 60% Revenue Growth, $153.7 Million in Cash, and Strong Sales Momentum. - AInvest
ImmunityBio's ANKTIVA Receives Buy Rating Amid Expanding Oncology Potential and Market Growth - AInvest
ImmunityBio Reports Q2 Earnings with 60% Revenue Increase, $43M in Sales, and 246% Unit Growth - AInvest
ImmunityBio 2025 Q2 Earnings Sustained Losses Amid Strong Revenue Surge - AInvest
ImmunityBio Reports Revenue Growth Amidst Continued Investments - TipRanks
ImmunityBio: Q2 Earnings Snapshot - Norwalk Hour
ImmunityBio’s Revenue Jumps On Bladder Cancer Drug Success - Finimize
ImmunityBio's Q2 Net Loss Narrows, Revenue Rises - MarketScreener
ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
ImmunityBio: Boral Capital raises PT to $30, maintains Buy rating. - AInvest
0.94%
1.72%
大文字化:
|
ボリューム (24 時間):